THANK YOU FOR SUBSCRIBING


Christian Buhlmann, Head of Business Development Europe & APACIn the past year, the industry saw significant changes in technology adoption, patient centricity, and remote access to sites. Trial continuity depended deeply on not only these aspects, but also on the staff and teams that were required to flex quickly to support those changes. Simply put, 2020 forced the industry to make leaps and bounds towards the goals that many of us were dreaming of for years.
In 2021 we have to be ready to adapt, adjust, and change again.
At PSI, we’ve seen significant growth in 2020 that will continue into 2021 and beyond. We’ve stayed true to our values as a privately owned, global CRO, and we’ve shifted many processes in order to adapt to the changing clinical space in a very short amount of time. Not only are we ready for another fast-paced, patient-focused year – we’re excited for it. We’re excited to help bring more drugs to market, we’re excited to continue partnering with pharma and biotech teams to put patients first, and we’re excited to continue adopting new processes and flexing quickly to deliver on-time. While we can’t predict the exact changes or disruptions that might take place, we’re excited for how we’ll handle the ever-shifting landscape in order to get care to the patients that need it.
Company
PSI CRO
Management
Christian Buhlmann, Head of Business Development Europe & APAC
Description